Molecular basis of the anti-cancer effects of genistein isoflavone in LNCaP prostate cancer cells

Functional Foods in Health and Disease

Volumn 1, Issue 3, 2011, Pages 91-105

  Merchant, K ^a   Kumi Diaka, J ^b   Rathinavelu, A ^c   Esiobu, N ^b   Zoeller, R ^b   Hartmann, J ^b   Johnson, M ^b  

^a BARRY UNIVERSITY   (United States)

^b FLORIDA ATLANTIC UNIVERSITY   (United States)

^c NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Chemotherapy; Expression of genes; Genistein isoflavone; Immunotherapy; Phytotherapeutic adjuvant; Prostate cancer

Indexed keywords

EID: 84873353861     PISSN: 23787007     EISSN: 21603855     Source Type: Journal    
DOI: 10.31989/ffhd.v1i3.137     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E et al. (2008) Cancer Statistics 2008. CA Cancer J Clin 58, 71-96.
2. Stanford JL, Stephenson RA, Coyle LM et al. (1998) Prostate Cancer Trends 1973-1995, SEER Program, National Cancer Institute. NIH Pub. No. 99-4543. Bethesda, MD.
3. Mettlin C. (1997). Recent developments in the epidemiology of prostate cancer. Eur J Cancer 33(3):340-347.
4. Marks LS, Kojima M, Demarzo A et al. (2004) Prostate Cancer in Native Japanese and Japanese American Men: Effects of Dietary Differences on Prostatic Tissue. Urology 64, 765-771.
5. Colli JL, Colli A. (2005) International comparisons of prostate cancer mortality rates with dietary practices and sunlight levels. Urol Oncol 23, 390-398.
6. Klassen AC, Platz EA. (2006) What Can Geography Tell Us About Prostate Cancer? Am J Prev Med 30, S7-S15?
7. Gao X, Porter AT, Grignon DJ et al. (1997) Diagnostic and Prognostic Markers for Human Prostate Cancer. Prostate 31, 264-281.
8. Baade PD, Coory MD, Aitken JF. (2004) International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control 15, 237-241.
9. Hasler CM, Blumberg JB. (1999) Symposium on Phytochemicals: Biochemistry and Physiology. American Society for Nutritional Sciences. 129, 756S-757S.
10. Dixon RA, Ferreira D. (2002) Genistein Phytochemistry 60, 205-211.
11. Sarkar FH, Yiwei L. (2002) Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev 21, 265-280.
12. Dalu A, Haskell JF, Coward L et al. (1998) Genistein, a component of soy, inhibits the expression of EGF and ErbB2/Neu receptors in the rat dorsolateral prostate. Prostate 37, 36-43.
13. Chen A, Donovan SM. (2004) Genistein at a Concentration Present in Soy Infant Formula Inhibits Caco-2BBe Cell Proliferation by Causing G2/M Cell Cycle Arrest. J Nutr 134, 1303-8.
14. Xu X, Harris K, Wang H et al. (1995) Bioavailability of soybean isoflavones depends upon gut microflora in women. J Nutr 125, 2307-2315.
15. Adlercreutz H, Markkanen H, Watanabe S. (1993) Plasma concentrations of phyto-estrogens in Japanese men. Lancet 342, 1209-10.
16. Glynn D, Sherman BT, Hosack DA et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4, P3.
17. Kanehisa M, Goto S, Kawashima S et al. (2002) The KEGG databases at Genome Net. Nucleic Acids Res 30, 42-46.
18. Kumi-Diaka J, Saddler-Shawnette S, Aller A et al. (2004) Potential mechanism of phytochemical-induced apoptosis in human prostate adenocarcinoma cells: Therapeutic synergy of genistein and β-lapachone combination treatment. Cancer Cell Int 4:5.
19. Merchant K. (2005) Anticancer Activity of Two Dietary Phytochemicals: Genistein Isoflavone and β-Lapachone. Master's thesis, Florida Atlantic University.
20. Zhou J, Gugger ET, Tanaka T et al. (1999) Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 129, 1628 1635.
21. Kumi-Diaka J, Butler A. (2000) Caspase-3 protease activation during the process of genistein-induced apoptosis in TM4 testicular cells. Biol Cell 92, 115-124.
22. Shi Y. (2002) Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 9, 459-470.
23. Takahashi Y, Lavigne JA, Hursting SD et al. (2004) Using DNA microarray analyses to elucidate the effects of genistein in androgen-responsive prostate cancer cells: Identification of novel targets. Mol Carcinog 41, 108-119.
24. Suzuki K, Koike H, Matsui H et al. (2002) Genistein, a soy isoflavone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3. Int J Cancer 99, 846-852.
25. De Boer L, Oakes V, Beamish H et al. (2008) Cyclin A/cdk2 coordinates centrosomal and nuclear mitotic events. Oncogene 27, 4261-4268.
26. Husdal A, Bukholm G, Bukholm IRK. (2006). The prognostic value and overexpression of cyclin A is correlated with gene amplification of both cyclin A and cyclin E in breast cancer patient. Cell Oncol 28, 107-116.
27. Soni DV, Sramkoski RM, Lam M et al. (2008) Cyclin B1 is rate limiting but not essential for mitotic entry and progression in mammalian somatic cells. Cell Cycle 7, 1285-300.
28. Shore GC, Viallet J. (2005) Modulating the Bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. Hematology 1, 226-230.
29. Kumi-Diaka J, Hassanhi KM, Merchant K et al. (2006) Influence of Genistein Isoflavone on Matrix Metalloproteinase-2 Expression in Prostate Cancer Cells. J Med Food 9, 491-97.
30. Guo Y, Wang S, Hoot DR et al. (2007) Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J Nutr Biochem 18, 408- 417.
31. Ladd AN, Nguyen NH, Malhotra K et al. (2004) CELF6, a Member of the CELF Family of RNA-binding Proteins, Regulates Muscle-specific Splicing Enhancer-dependent Alternative Splicing. J Biol Chem 279, 17756-17764.
32. Paillard L, Omilli F, Legagneux V et al. (1998) EDEN and EDEN-BP, a cis element and an associated factor that mediate sequence-specific mRNA deadenylation in Xenopus embryos. EMBO J 17, 278-287.
33. Tomasini R, Samir AA, Carrier A et al. (2003) TP53INP1s and Homeodomain-interacting Protein Kinase-2 (HIPK2) Are Partners in Regulating p53 Activity. J Biol Chem 278, 37722-37729.
34. Takei Y, Ishikawa S, Tokino T et al. (1998) Isolation of a novel TP53 target gene from a colon cancer cell line carrying a highly regulated wild-type TP53 expression system. Genes Chromosomes Cancer 23, 1-9.